Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ: SGMO )

2.500 +0.110 (+4.60%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,521,419
Open 2.320
Bid (Size) 2.410 (100)
Ask (Size) 2.500 (3)
Prev. Close 2.390
Today's Range 2.290 - 2.500
52wk Range 0.3040 - 3.179
Shares Outstanding 145,337,046
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US Stocks Likely To Open Higher After Plunging On Powell's Hawkish Comments: Analyst Calls It A 'Healthy' Reaction From An 'Overly Optimistic' Market
U.S. stock futures climbed on Thursday in premarket hours after a hawkish cut from the Federal Reserve on Wednesday. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
+349.40%
+349.40%
1 Month
+28.87%
+28.87%
3 Month
+169.92%
+169.92%
6 Month
+459.79%
+459.79%
1 Year
+425.65%
+425.65%

More News

Read More
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
From Sangamo Therapeutics, Inc.
Via Business Wire
The Analyst Landscape: 6 Takes On Sangamo Therapeutics
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Sangamo Therapeutics's Earnings Outlook
Via Benzinga
4 Analysts Have This To Say About Sangamo Therapeutics
Via Benzinga
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
Via InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
What's Going On With Sangamo Therapeutics Shares Tuesday?
Via Benzinga
Exposures Product Safety
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Falls Over 150 Points; General Motors Tops Q3 Views
Via Benzinga
Topics Stocks
Exposures US Equities
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
From Sangamo Therapeutics, Inc.
Via Business Wire
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Via Benzinga
Exposures Product Safety
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Why Sangamo Therapeutics Stock Is Soaring
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.